Biogen: Sclerosis trials

The registry lists 137 Sclerosis studies with Biogen as lead sponsor. 0 are open to participants now and 49 have results posted.

Phase 1 9Phase 2 20Phase 3 36Phase 4 31No phase 43(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04579666Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsTerminatedNCT03870763Phase 3Results posted
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationCompletedNCT03689972Phase 3Results posted
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)TerminatedNCT03222973Phase 2Results posted
• A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2CompletedNCT03093324Phase 3Results posted
• Efficacy and Safety of Daclizumab in Participants With RRMS Switching From NatalizumabTerminatedNCT02881567Phase 3Results posted
• A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1CompletedNCT02634307Phase 3Results posted
• An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02623699Phase 3Results posted
• Plegridy Satisfaction Study in ParticipantsCompletedNCT02587065Phase 4Results posted
• Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02555215Phase 3Results posted
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).CompletedNCT02525874Phase 3Results posted
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisTerminatedNCT02430532Phase 3Results posted
• Tecfidera Slow-Titration StudyTerminatedNCT02428231Phase 3Results posted
• Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TecfideraCompletedNCT02410278Phase 4Results posted
• Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMSCompletedNCT02410200Phase 2Results posted
• Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.TerminatedNCT02343159Phase 4Results posted
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedNCT02342704Phase 4Results posted
• Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other TherapiesTerminatedNCT02241785Phase 4Results posted
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple SclerosisCompletedNCT02219932Phase 3Results posted
• Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyCompletedNCT02125604Phase 4Results posted
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.CompletedNCT02097849Phase 2Results posted
• Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT02090413Phase 4Results posted
• Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)CompletedNCT01939002Phase 3Results posted
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United StatesCompletedNCT01873417Phase 4Results posted
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With AvonexCompletedNCT01864148Phase 2Results posted
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedNCT01797965Phase 3Results posted
• Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisCompletedNCT01480076Phase 4Results posted
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedNCT01462318Phase 3Results posted
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT01440101Phase 2/3Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• Long-Term Safety and Efficacy Study of Peginterferon Beta-1aCompletedNCT01332019Phase 3Results posted
• BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisCompletedNCT01156311Phase 2Results posted
• Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01064401Phase 3Results posted
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisTerminatedNCT01058005Phase 3Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT01051349Phase 2Results posted
• Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisCompletedNCT00906399Phase 3Results posted
• A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00871780Phase 4Results posted
• Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00870740Phase 2Results posted
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)CompletedNCT00835770Phase 3Results posted
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis SubjectsCompletedNCT00828204Phase 3Results posted
• Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsTerminatedNCT00784836Phase 3Results posted
• The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisCompletedNCT00536120Phase 4Results posted
• Natalizumab High Titer Immunogenicity and SafetyCompletedNCT00516893Phase 2Results posted
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisCompletedNCT00420212Phase 3Results posted
• Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisCompletedNCT00390221Phase 2Results posted
• Natalizumab Re-Initiation of DosingCompletedNCT00306592Phase 3Results posted
• Natalizumab (Tysabri) Re-Initiation of DosingTerminatedNCT00297232Phase 3Results posted
• A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsCompletedNCT06127095
• A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) ParticipantsTerminatedNCT05701423
• A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaCompletedNCT05658484Phase 4
• A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT05532163Phase 4
• TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated ParticipantsCompletedNCT05236777
• Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination StudyTerminatedNCT05197699
• MS PATHS COVID-19 Questionnaire Data Linkage Sub-StudyCompletedNCT05058729
• Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral SclerosisApproved for marketingNCT04972487
• Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsCompletedNCT04832399
• Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple SclerosisCompletedNCT04756700Not applicable
• Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by TecfideraCompletedNCT04756687
• Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support ProgramCompletedNCT04655222
• Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT04288856Phase 1
• Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEPCompletedNCT04221191
• Scan-Rescan Sub-Study of MS PATHSCompletedNCT04123353
• Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)WithdrawnNCT04079088Phase 2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral SclerosisCompletedNCT03945279Phase 1
• Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple SclerosisTerminatedNCT03926637
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral SclerosisCompletedNCT03626012Phase 1
• A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple SclerosisCompletedNCT03347370
• Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyCompletedNCT03177083Phase 4
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT02776072
• MSPT Device Usability StudyCompletedNCT02664324
• Methodology Study of Novel Outcome Measures to Assess Progression of ALSCompletedNCT02611674
• Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012CompletedNCT02579681Phase 3
• Tecfidera Lymphocyte Chart ReviewCompletedNCT02519413
• Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple SclerosisWithdrawnNCT02472938Phase 4
• Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)WithdrawnNCT02428218Phase 3
• Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)TerminatedNCT02323269
• Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon TherapyWithdrawnNCT02234869Phase 4
• Plegridy Observational ProgramCompletedNCT02230969
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)CompletedNCT02159573
• Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT02142205Phase 4
• Natalizumab Subcutaneous Immunogenicity and Safety StudyTerminatedNCT02142192Phase 2
• Safety and Efficacy in Pediatric MS Patients Prescribed TysabriCompletedNCT02137109
• Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateWithdrawnNCT02090348Phase 4
• Tolerability and Quality of Life Study in Participants Who Switched to Avonex PenCompletedNCT02076841
• Dimethyl Fumarate (DMF) Observational StudyCompletedNCT02047097
• A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported OutcomesCompletedNCT01930708Phase 4
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
• Biogen Multiple Sclerosis Pregnancy Exposure RegistryCompletedNCT01911767
• Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMSCompletedNCT01903291
• PK and PD Study of Natalizumab in Pediatric Subjects With RRMSCompletedNCT01884935Phase 1
• An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01838668Phase 3
• Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsTerminatedNCT01706107
• Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.CompletedNCT01597297Phase 2
• Canadian Avonex PEN Productivity StudyCompletedNCT01489748
• Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsCompletedNCT01485003
• Avonex PEN Satisfaction and Patients Experience Clinical TrialCompletedNCT01366040
• Safety Study of BIIB033 in Subjects With Multiple SclerosisCompletedNCT01244139Phase 1
• Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.CompletedNCT01235221Phase 3